Cargando…

Cost, outcomes, treatment pathways and challenges for diabetes care in Italy

BACKGROUND: In Italy both incidence and prevalence of diabetes are increasing and age at diagnosis is decreasing in type 2 diabetes. Diabetes is one of the major causes of morbidity in Italy, causing several disabilities and affecting the economically active population. The objective of this paper i...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimaccia, Federico, Kanavos, Panos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110929/
https://www.ncbi.nlm.nih.gov/pubmed/25024101
http://dx.doi.org/10.1186/1744-8603-10-58
_version_ 1782328038661292032
author Grimaccia, Federico
Kanavos, Panos
author_facet Grimaccia, Federico
Kanavos, Panos
author_sort Grimaccia, Federico
collection PubMed
description BACKGROUND: In Italy both incidence and prevalence of diabetes are increasing and age at diagnosis is decreasing in type 2 diabetes. Diabetes is one of the major causes of morbidity in Italy, causing several disabilities and affecting the economically active population. The objective of this paper is to identify and discuss costs, outcomes and some of the challenges of diabetes care in Italy in the context of recent policy changes. METHODS: The study collected data and evidence from both primary and secondary sources. A total of 10 experts, including clinicians (diabetologists/endocrinologists) and decision makers, both at national and regional levels, were interviewed through face-to-face semi-structured interviews. The secondary sources include peer review literature from Medline, grey literature, reports from national and international sources, including professional bodies and organizations. RESULTS: The total direct cost of diabetes for the Italian NHS in 2012 is estimated to be above €9 billion, of which more than half for hospital admissions (57%), and the remaining half for drugs (30%) and outpatient care (13%). However, there is scant evidence on indirect and intangible costs of diabetes in Italy. The quality of care addressed via the AMD Annals found overall good performance with both process and intermediate outcome indicators showing positive and improving results from 2004 to 2011, except for few parameters, including renal function and foot monitoring, which are still inadequate. Major challenges are the rising diabetes prevalence, the difficulty in meeting the rising demand for care and the scant development of multidisciplinary delivery of care, especially in the predominantly ambulatory setting of the Southern diabetes centres. CONCLUSIONS: Prevention of diabetes, especially adopting a multi-sectorial approach, should be further empowered by policy makers through promoting healthy lifestyles and specifically targeting child obesity. Other key strategies include more information and education, better diabetes management through the adoption of a chronic model of care, more focus on appropriateness and efficiency of care and better communication between diabetes centres within every Region.
format Online
Article
Text
id pubmed-4110929
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41109292014-07-26 Cost, outcomes, treatment pathways and challenges for diabetes care in Italy Grimaccia, Federico Kanavos, Panos Global Health Research BACKGROUND: In Italy both incidence and prevalence of diabetes are increasing and age at diagnosis is decreasing in type 2 diabetes. Diabetes is one of the major causes of morbidity in Italy, causing several disabilities and affecting the economically active population. The objective of this paper is to identify and discuss costs, outcomes and some of the challenges of diabetes care in Italy in the context of recent policy changes. METHODS: The study collected data and evidence from both primary and secondary sources. A total of 10 experts, including clinicians (diabetologists/endocrinologists) and decision makers, both at national and regional levels, were interviewed through face-to-face semi-structured interviews. The secondary sources include peer review literature from Medline, grey literature, reports from national and international sources, including professional bodies and organizations. RESULTS: The total direct cost of diabetes for the Italian NHS in 2012 is estimated to be above €9 billion, of which more than half for hospital admissions (57%), and the remaining half for drugs (30%) and outpatient care (13%). However, there is scant evidence on indirect and intangible costs of diabetes in Italy. The quality of care addressed via the AMD Annals found overall good performance with both process and intermediate outcome indicators showing positive and improving results from 2004 to 2011, except for few parameters, including renal function and foot monitoring, which are still inadequate. Major challenges are the rising diabetes prevalence, the difficulty in meeting the rising demand for care and the scant development of multidisciplinary delivery of care, especially in the predominantly ambulatory setting of the Southern diabetes centres. CONCLUSIONS: Prevention of diabetes, especially adopting a multi-sectorial approach, should be further empowered by policy makers through promoting healthy lifestyles and specifically targeting child obesity. Other key strategies include more information and education, better diabetes management through the adoption of a chronic model of care, more focus on appropriateness and efficiency of care and better communication between diabetes centres within every Region. BioMed Central 2014-07-14 /pmc/articles/PMC4110929/ /pubmed/25024101 http://dx.doi.org/10.1186/1744-8603-10-58 Text en Copyright © 2014 Grimaccia and Kanavos; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Grimaccia, Federico
Kanavos, Panos
Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
title Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
title_full Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
title_fullStr Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
title_full_unstemmed Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
title_short Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
title_sort cost, outcomes, treatment pathways and challenges for diabetes care in italy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110929/
https://www.ncbi.nlm.nih.gov/pubmed/25024101
http://dx.doi.org/10.1186/1744-8603-10-58
work_keys_str_mv AT grimacciafederico costoutcomestreatmentpathwaysandchallengesfordiabetescareinitaly
AT kanavospanos costoutcomestreatmentpathwaysandchallengesfordiabetescareinitaly